The companies and academics are working to assess challenges and seek opportunities that could influence Duchenne Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players such as Sarepta Therapeutics, Pfizer, Santhera Pharmaceuticals, Taiho Pharmaceuticals, and others are involved in developing therapies for Duchenne Muscular Dystrophy. The launch of emerging therapies will significantly impact the Duchenne Muscular Dystrophy market.
DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Duchenne Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Duchenne Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Duchenne Muscular Dystrophy: An Overview
Duchenne Muscular Dystrophy is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females. DMD causes progressive weakness and loss (atrophy) of skeletal and heart muscles,
DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3–5. The disease primarily affects boys, but in rare cases, it can affect girls. DMD is inherited as an X-linked disease. X-linked genetic disorders are conditions caused by an abnormal gene on the X chromosome and manifest mostly in males. Females with a defective gene on one of their X chromosomes are carriers for that disorder.
According to the National Institute of Health, US. Duchenne Muscular Dystrophy is a rare muscle disorder, but it is one of the most frequent genetic conditions, affecting approximately 1 in 3,500 male births worldwide. It is usually recognized between three and six years of age.
Duchenne Muscular Dystrophy Market Key Facts
The market size of Duchenne Muscular Dystrophy in the seven major markets was USD 745.4 Million in 2020.
The United States accounts for the largest market size of Duchenne Muscular Dystrophy in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The United States accounted for the largest market size of DMD, USD 623.7 Million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Japan accounted for USD 22.7 Million in 2020, which is expected to rise during the forecast period.
The total prevalent population of Duchene muscular dystrophy (DMD) in the 7MM was found to be 30,688 in 2020.
Epidemiology assessed for DMD showed that the US, in 2020, accounted for approximately 16,765 prevalent cases of DMD.
In the United States, the maximum number of DMD patients affected was 3,185 with Attention-deficit hyperactivity disorder (ADHD), followed by 3,353 with Scoliosis cases, 2,515 with Cardiomyopathy cases, 2,180 with Obsessive-compulsive disorder (OCD) cases in 2020, and several other comorbidities.
Among the EU-5 countries in 2020, the UK had the highest prevalent population of DMD patients, with 2,622 cases, followed by Germany (2,596) and France (2,101). In contrast, Spain had the lowest cases (1,478) in 2020.
In the United States, in 2020, the highest proportion of age-specific cases was observed in 5–9 years, followed by age groups of 10–14 years and 15–20 years.
In Japan, 2,571 large mutation and 643 small mutation cases were observed in 2020.
Duchenne Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Duchenne Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Duchenne Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Duchenne Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Duchenne Muscular Dystrophy Epidemiology, Segmented as –
Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
Age-specific Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
Mutation-specific Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
Ambulatory and non-ambulatory Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]
Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Duchenne Muscular Dystrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Leading Companies in the Duchenne Muscular Dystrophy Therapeutics Market Include:
Antisense Therapeutics
Bioleaders Corporation
Capricor
Daiichi Sankyo
FibroGen
Italfarmaco
Mitobridge
Nippon Shinyaku
Pfizer
PTC Therapeutics
ReveraGen BioPharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Solid Biosciences
Taiho Pharmaceutical
Vertex Pharmaceuticals
WaVe life Sciences
And Many Others
Duchenne Muscular Dystrophy Marketed and Emerging Therapies Covered in the Report Include
Vyondys 53 (Golodirsen): Sarepta Therapeutics
Emflaza: PTC Therapeutics
Exondys 51: Sarepta Therapeutics
Translarna: PTC Therapeutics
Amondys 45: Sarepta Therapeutics
Viltepso: Nippon Shinyaku
PF-06939926: Pfizer
Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
Pizuglanstat (TAS-205): Taiho Pharmaceutical
Givinostat: Italfarmaco
CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals
WVE N531: WaVe life Sciences
Pamrevlumab: FibroGen
TAS-205: Taiho Pharmaceutical
MA-0211: Mitobridge
BLS-M22: Bioleaders Corporation
CAP 1002: Capricor
DS-5141: Daiichi Sankyo
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis
4. Duchenne Muscular Dystrophy Market Overview at a Glance
5. Duchenne Muscular Dystrophy Disease Background and Overview
6. Duchenne Muscular Dystrophy Patient Journey
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Duchenne Muscular Dystrophy Unmet Needs
10. Key Endpoints of Duchenne Muscular Dystrophy Treatment
11. Duchenne Muscular Dystrophy Marketed Products
12. Duchenne Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Duchenne Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Duchenne Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Duchenne Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Duchenne Muscular Dystrophy Market
18. Duchenne Muscular Dystrophy Market Drivers
19. Duchenne Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
